Clinical trials data
Verbal Fluency in cardiovascular trials: 61 registered studies
Every registered cardiovascular disease study on ClinicalTrials.gov that names Verbal Fluency in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered cardiovascular disease studies name it in an outcome measure
- 61
- Name it in a primary outcome, 34%
- 21 of 61
Tests named in the same studies
- 1
Trail Making Test29 studies, 10 as a primary outcome
- 2
Verbal Learning26 studies, 8 as a primary outcome
- 3
Digit Span Test22 studies, 4 as a primary outcome
- 4
Stroop Color-Word Test16 studies, 5 as a primary outcome
- 5
Category Fluency11 studies, 4 as a primary outcome
- 6
Symbol Coding10 studies, 2 as a primary outcome
- 7
Picture Naming Test8 studies, 4 as a primary outcome
- 8
Complex Figure Copy and Recall6 studies, 1 as a primary outcome
- 9
Clock Drawing Task5 studies, 1 as a primary outcome
- 10
Task Switching Test4 studies, 2 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 2 | 1 |
| 2011 | 2 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 5 | 2 |
| 2015 | 5 | 2 |
| 2016 | 5 | 1 |
| 2017 | 2 | 1 |
| 2018 | 2 | 2 |
| 2019 | 1 | 0 |
| 2020 | 7 | 4 |
| 2021 | 5 | 3 |
| 2022 | 5 | 0 |
| 2023 | 6 | 1 |
| 2024 | 3 | 0 |
| 2025 | 5 | 2 |
| 2026 | 4 | 1 |
Phases and study sizes
By phase
- Early phase 11 studies, 0 as a primary outcome
- Phase 11 studies, 0 as a primary outcome
- Phase 24 studies, 2 as a primary outcome
- Phase 31 studies, 1 as a primary outcome
- Phase 43 studies, 0 as a primary outcome
- Not applicable33 studies, 10 as a primary outcome
- Observational18 studies, 8 as a primary outcome
Participants per study
- Not applicable60 median, 29 to 138
- Observational150 median, 80 to 600
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Not applicable | 31 | 60 | 29 to 138 |
| Observational | 17 | 150 | 80 to 600 |
When cardiovascular trials measure it
Latest time point of each outcome
- Within a day6 outcomes, 0 as a primary outcome
- Up to 4 weeks4 outcomes, 2 as a primary outcome
- 1 to 3 months7 outcomes, 1 as a primary outcome
- 3 to 6 months15 outcomes, 4 as a primary outcome
- 6 to 12 months14 outcomes, 5 as a primary outcome
- 1 to 2 years8 outcomes, 5 as a primary outcome
- Over 2 years6 outcomes, 3 as a primary outcome
- No duration given1 outcomes, 1 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
60 of the 61 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting13 studies, 3 as a primary outcome
- Not yet recruiting4 studies, 1 as a primary outcome
- Active, not recruiting4 studies, 0 as a primary outcome
- Completed26 studies, 13 as a primary outcome
- Stopped early5 studies, 2 as a primary outcome
- Status unknown9 studies, 2 as a primary outcome
What they test
- Behavioral9 studies, 3 as a primary outcome
- Drug9 studies, 2 as a primary outcome
- Device9 studies, 1 as a primary outcome
- Dietary supplement4 studies, 1 as a primary outcome
- Procedure12 studies, 4 as a primary outcome
- Diagnostic test4 studies, 2 as a primary outcome
- Biological2 studies, 1 as a primary outcome
- Other21 studies, 6 as a primary outcome
- None given6 studies, 4 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States27 studies, 8 as a primary outcome
- Canada6 studies, 0 as a primary outcome
- China4 studies, 0 as a primary outcome
- France4 studies, 1 as a primary outcome
- Brazil3 studies, 1 as a primary outcome
- Denmark3 studies, 1 as a primary outcome
- Italy3 studies, 3 as a primary outcome
- Türkiye2 studies, 1 as a primary outcome
- Germany1 studies, 0 as a primary outcome
- Netherlands1 studies, 0 as a primary outcome
- Slovakia1 studies, 0 as a primary outcome
- Spain1 studies, 1 as a primary outcome
15 countries in all. A study with sites in several counts in each; 4 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed cardiovascular disease studies that name Verbal Fluency: 13 of 26, 50%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed cardiovascular disease studies that name Verbal Fluency | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 4, 15% | 776, 10% |
| Results on ClinicalTrials.gov only | 6, 23% | 1,139, 14% |
| A results paper only | 3, 12% | 1,711, 22% |
| Neither | 13, 50% | 4,327, 54% |
The 61 studies
61 studies match. 21 name Verbal Fluency in a primary outcome. Median size 100 participants. Median time to the primary outcome: 12 months.
Loading 61 studies; the filters turn on when they arrive.
2026 is partly planned starts.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 2 | 1 |
| 2011 | 2 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 5 | 2 |
| 2015 | 5 | 2 |
| 2016 | 5 | 1 |
| 2017 | 2 | 1 |
| 2018 | 2 | 2 |
| 2019 | 1 | 0 |
| 2020 | 7 | 4 |
| 2021 | 5 | 3 |
| 2022 | 5 | 0 |
| 2023 | 6 | 1 |
| 2024 | 3 | 0 |
| 2025 | 5 | 2 |
| 2026 | 4 | 1 |
Library tests named most
Conditions
Phases
Participants
Lead sponsor: other 61. Interventional 43, observational 18.
As a primary outcomeSecondary or other outcomeVerbal Fluency
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07692958 | Start2026 | PhaseNot applicable | ConditionsCardiovascular disease | Participants160 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07626567 | Start2026 | PhaseObservational | ConditionsDelirium, surgery and intensive care, Cardiovascular disease | Participants500 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07607795 | Start2026 | PhaseNot applicable | ConditionsCardiovascular disease | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07259434 | Start2026 | PhaseNot applicable | ConditionsCancer, Cardiovascular disease | Participants152 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06867198 | Start2025 | PhaseNot applicable | ConditionsObesity and diabetes, Cardiovascular disease | Participants72 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06857994 | Start2025 | PhaseObservational | ConditionsObesity and diabetes, Cardiovascular disease | Participants101 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06740513 | Start2025 | PhaseObservational | ConditionsStroke, Cardiovascular disease | Participants1,000 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06735599 | Start2024 | PhaseNot applicable | ConditionsObesity and diabetes, Cardiovascular disease | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06680973 | Start2025 | PhaseNot applicable | ConditionsCardiovascular disease | Participants33 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT06336174 | Start2022 | PhaseObservational | ConditionsStroke, Cardiovascular disease | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06252376 | Start2025 | PhaseNot applicable | ConditionsParkinson's disease, Cardiovascular disease | ParticipantsNot given | Lead sponsorOther | StatusStopped early | Library tests named
|
| NCT06027788 | Start2023 | PhaseNot applicable | ConditionsStroke, Delirium, surgery and intensive care, Cardiovascular disease | Participants842 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT05824650 | Start2023 | PhaseObservational | ConditionsAging, frailty and exercise, Cardiovascular disease | Participants43 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT05790707 | Start2023 | PhaseNot applicable | ConditionsMild cognitive impairment, Cardiovascular disease | Participants120 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05785871 | Start2020 | PhaseObservational | ConditionsMild cognitive impairment, Cardiovascular disease | Participants80 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT05756257 | Start2024 | PhaseObservational | ConditionsStroke, Cardiovascular disease | Participants150 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05708807 | Start2018 | PhaseObservational | ConditionsStroke, Cardiovascular disease | Participants600 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05647473 | Start2024 | PhasePhase 2 | ConditionsDementia and Alzheimer's, Cardiovascular disease | Participants66 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT05595577 | Start2023 | PhaseNot applicable | ConditionsCancer, Cardiovascular disease | Participants105 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT05539261 | Start2022 | PhaseObservational | ConditionsCardiovascular disease | Participants30 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT05400174 | Start2021 | PhaseNot applicable | ConditionsParkinson's disease, Cardiovascular disease | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05369520 | Start2023 | PhaseNot applicable | ConditionsCardiovascular disease | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05230927 | Start2020 | PhaseObservational | ConditionsCardiovascular disease, Lung disease | Participants240 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT05223426 | Start2023 | PhaseNot applicable | ConditionsCardiovascular disease | Participants54 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT05173740 | Start2022 | PhasePhase 4 | ConditionsCardiovascular disease | Participants214 | Lead sponsorOther | StatusRecruiting | Library tests named
|
Questions, answered from the data
How many cardiovascular trials use Verbal Fluency?
61 registered cardiovascular disease studies on ClinicalTrials.gov name it in an outcome measure, 21 of them in a primary outcome: 9% of the condition's 682 studies with a cognitive outcome, against 11% of all of them. It is the 4th most named test in cardiovascular trials.
Which tests do cardiovascular trials use with Verbal Fluency?
The Trail Making Test (29 studies), Verbal Learning (26 studies) and the Digit Span Test (22 studies).
When do cardiovascular trials measure Verbal Fluency?
Half of the primary outcomes that name Verbal Fluency are measured within 12 months of the start, and the middle half from 5 months to 2 years. 20 primary outcomes give a duration.
How many completed cardiovascular trials that use Verbal Fluency have reported results?
13 of the 26 completed studies that name it, 50%, have reported results: 10 posted them on ClinicalTrials.gov, 7 have a results paper linked to the registry record, and 4 did both. The other 13 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
Run Verbal Fluency in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.